A detailed history of Pdt Partners, LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 36,099 shares of DSGN stock, worth $202,876. This represents 0.02% of its overall portfolio holdings.

Number of Shares
36,099
Previous 27,127 33.07%
Holding current value
$202,876
Previous $90,000 115.56%
% of portfolio
0.02%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.19 - $5.88 $28,620 - $52,755
8,972 Added 33.07%
36,099 $194,000
Q2 2024

Aug 15, 2024

BUY
$3.23 - $4.77 $87,620 - $129,395
27,127 New
27,127 $90,000
Q4 2023

Feb 14, 2024

SELL
$1.99 - $2.76 $10,509 - $14,575
-5,281 Reduced 15.68%
28,401 $75,000
Q3 2023

Nov 14, 2023

SELL
$2.05 - $8.14 $28,351 - $112,576
-13,830 Reduced 29.11%
33,682 $79,000
Q2 2023

Aug 14, 2023

SELL
$4.99 - $7.64 $62,160 - $95,171
-12,457 Reduced 20.77%
47,512 $299,000
Q1 2023

May 15, 2023

BUY
$5.5 - $9.77 $329,829 - $585,897
59,969 New
59,969 $346,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $314M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.